Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.88 -0.44 (-0.43%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
94 95 Next >
Merck Completes Acquisition of EyeBio
From Merck & Co., Inc.
Via Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Merck & Co Unusual Options Activity
Via Benzinga
Insights Into Merck &amp; Co's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus 
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Uncover top picks in undervalued blue-chip stocks, unfairly punished yet consistently delivering strong operational results 
Via InvestorPlace
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... 
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
These are the blue-chip stocks to buy as they represent fundamentally strong companies with robust free cash flow visibility 
Via InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
Via Benzinga
Exposures COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best and worst performers. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Merck Stock On Monday?
Merck secures exclusive global rights to develop and commercialize opevesostat (MK-5684/ODM-208) for hormone-dependent cancers. Orion is eligible for milestone payments up to $1.63 billion and tiered... 
Via Benzinga
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
From Merck & Co., Inc.
Via Business Wire
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
With Washington likely having to take steps to cut the U.S. deficit within the next few years, here are three sectors at risk. 
Via InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
These are the undervalued blue-chip stocks to buy as they represent companies with a steady growth and robust cash flow outlook. 
Via InvestorPlace
What's Going On With Merck Stock On Friday?
The CDC's Advisory Committee on Immunization Practices recommends Merck's Capvaxive for adults 65+ and certain at-risk individuals 19-64. Merck also announces CHMP's positive recommendation for... 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc
Via Business Wire
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
From Merck & Co., Inc.
Via Business Wire
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
The FDA rejected Merck's Daiichi Sankyo-partnered antibody drug conjugate. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
This Recent FDA Approval Is Bad News for Pfizer
One of the pharma giant's top-selling products is about to face some intense competition. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
94 95 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.